Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28533907
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Gastroenterol+Rep+(Oxf)
2017 ; 5
(2
): 90-103
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Novel treatment options for portal hypertension
#MMPMID28533907
Schwabl P
; Laleman W
Gastroenterol Rep (Oxf)
2017[May]; 5
(2
): 90-103
PMID28533907
show ga
Portal hypertension is most frequently associated with cirrhosis and is a major
driver for associated complications, such as variceal bleeding, ascites or
hepatic encephalopathy. As such, clinically significant portal hypertension forms
the prelude to decompensation and impacts significantly on the prognosis of
patients with liver cirrhosis. At present, non-selective ?-blockers, vasopressin
analogues and somatostatin analogues are the mainstay of treatment but these
strategies are far from satisfactory and only target splanchnic hyperemia. In
contrast, safe and reliable strategies to reduce the increased intrahepatic
resistance in cirrhotic patients still represent a pending issue. In recent
years, several preclinical and clinical trials have focused on this latter
component and other therapeutic avenues. In this review, we highlight novel data
in this context and address potentially interesting therapeutic options for the
future.
free
free
free
